logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
G

Genmab

Scholars376
Papers177
Citations1
Related Papers (176)
Publication Date
delete
NAStructuralDB : structural database to facilitate computational studies of molecular modeling and recognition of proteins with special focus on antibody–antigen interactions
errmAbs
IF7.3
err2026-03-08
err0
errOAAI
errDawid Chomicz; Paweł Dudzic; Sonia Wrobel; Tomasz Gawlowski; Samuel Demharter; Roberto Spreafico; Hervé Minoux; Andrew Phillips; Konrad Krawczyk
errShare
errSave
Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial
errInternational Journal of Gynecological Cancer
IF4.7
err2025-12-31
err0
PREAI
errKan Yonemori; Shin Nishio; Shiro Suzuki; Kosei Hasegawa; Mayu Yunokawa; Satoshi Yamaguchi; Aikou Okamoto; Kazuto Nakamura; Shoji Kamiura; Keiichi Fujiwara; Noriyuki Katsumata; Hiroaki Kobayashi; Tomoka Usami; Ayako Mochizuki; Kazuhiro Takehara; Elizabeth Whalley; Hidehisa Noguchi; Ibrahima Soumaoro; Brian Slomovitz; Ignace Vergote
errShare
errSave
AbDesign: database of point mutants of antibodies with associated structures reveals poor generalization of binding predictions from machine learning models
errMABS
IF7.3
err2025-12-31
err1
PREAI
errJanusz, Bartosz; Chomicz, Dawid; Demharter, Samuel; Arts, Marloes; de Kanter, Jurrian; Wilke, Yano; Britze, Helena; Wrobel, Sonia; Gawlowski, Tomasz; Dudzic, Pawel; Ukkivi, Kart; Peil, Lauri; Spreafico, Roberto; Krawczyk, Konrad
errShare
errSave
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial
errThe Lancet Haematology
IF0
err2025-12-08
err0
PREAI
errArnon P Kater; Ann Janssens; Herbert Eradat; Fritz Offner; Jose D Sandoval-Sus; Mazyar Shadman; Christian Bjørn Poulsen; Jacob Haaber Christensen; Meghan C Thompson; Meijian Guan; Andrew J Steele; Marcia Rios; Marie Holst Mørch; Toshihiko Oki; Rebecca Valentin; Mar Bellido; Barbara Eichhorst
errShare
errSave
Multimodality Investigative Pathology: Leveraging the Full Potential of Spatial Pathobiology in Pharmaceutical Therapeutic Discovery and Development
errTOXICOLOGIC PATHOLOGY
IF1.8
err2025-11-01
err0
PREAI
errKavirayani, Anoop; Kaliyaperumal, Saravanan; Saravanan, Chandra; Guan, Meijian; Roscoe, Nathaniel; Siso, Silvia; Clark, Elizabeth; Cornax, Ingrid; Carreira, Vinicius
errShare
errSave
Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis
errClinical Lymphoma Myeloma and Leukemia
IF2.7
err2025-10-13
err0
errOAAI
errJavier Munoz; Allison Rosenthal; Andrew Ip; Justin M. Darrah; Tongsheng Wang; Guihua Zhang; Alex Mutebi; Tychell Branchcomb; Zhijie Ding; Anindit Chhibber; Fernando Rivas Navarro; Malene Risum; Mohammad Atiya; Samantha Brodkin; Anthony Wang; Abualbishr Alshreef; Diala Harb; Mariana Sacchi; Daniela Hoehn; Yasmin H. Karimi
errShare
errSave
Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin
errJOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
IF2.8
err2025-10-01
err0
errOAAI
errFeng, Summer; Gunawan, Rudy; Passey, Chaitali; Voellinger, Jenna; Polhamus, Daniel; Gerritsen, Arnout; O'Day, Christine; Carret, Anne-Sophie; Soumaoro, Ibrahima; Gupta, Manish; Hanley, William D.
errShare
errSave
Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma
errBlood
IF23.1
err2025-09-10
err0
errOAAI
errLorenzo Falchi; Anna Sureda; Sirpa Leppä; Joost S.P. Vermaat; Marcel Nijland; Jacob Haaber Christensen; Sven de Vos; Harald Holte; Reid W. Merryman; Pieternella J. Lugtenburg; Pau Abrisqueta; Kim M. Linton; Gauri Sunkersett; Daniela Hoehn; Ali Rana; Aqeel Abbas; Jennifer Marek; Yi Hao; Andrew J. Steele; Christopher Morehouse; Martin Hutchings; David Belada
errShare
errSave
Clinical representativeness of pivotal trials for T-cell engagers in relapsed/refractory follicular lymphoma
errFuture Oncology
IF2.6
err2025-08-13
err0
errOAAI
errZhijie Ding; Guihua Zhang; Junhua Yu; Tongsheng Wang; Rajesh Kamalakar; Savreet Bains Chawla; Anindit Chhibber; Anthony Wang; Abualbishr Alshreef; David Tybor; Felipe Marques Goncalves; Fernando Rivas Navarro; Mohammad Atiya; Elena Favaro; Alex Mutebi
errShare
errSave
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma
errBlood Advances
IF7.1
err2025-06-09
err0
errOAAI
errAlexey V. Danilov; Swetha Kambhampati Thiruvengadam; Kim Linton; Karen Cumings; Viktor Chirikov; Alex Mutebi; Savreet Bains Chawla; Anindit Chhibber; Fernando Rivas Navarro; Felipe Marques Gonçalves; Anthony Wang; Zhijie Ding; Abualbishr Alshreef; Elena Favaro; Daniela Hoehn; Anna Sureda
errShare
errSave
Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell Lymphoma
errCLINICAL PHARMACOLOGY & THERAPEUTICS
IF5.5
err2025-02-11
err0
errOAAI
errLi, Tommy; Gibiansky, Leonid; Parikh, Apurvasena; Putnins, Matthew; Chiu, Christopher W.; Sacchi, Mariana; Feng, Huaibao; Ahmadi, Tahamtan; Gupta, Manish; Xu, Steven
errShare
errSave
Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
errFRONTIERS IN ONCOLOGY
IF3.3
err2025-02-10
err0
errOAAI
errLloyd, Katy; Middelburg, Jim; Ovcinnikovs, Vitalijs; Pencheva, Nora; Kemper, Kristel; van Hall, Thorbald
errShare
errSave
VIBE: an R-package for VIsualization of Bulk RNA Expression data for therapeutic targeting and disease stratification
errFRONTIERS IN ONCOLOGY
IF3.3
err2025-01-29
err0
errOAAI
errKhatri, Indu; van Asten, Saskia D.; Moreno, Leandro F.; Higgs, Brandon W.; Klijn, Christiaan; Blokzijl, Francis; Kolder, Iris C. R. M.
errShare
errSave
Marked hemoglobin mass expansion and plasma volume contraction in Sherpas acclimatizing to 5,400 m altitude
errJOURNAL OF APPLIED PHYSIOLOGY
IF3.3
err2024-12-01
err0
PREAI
errRoche, Johanna; Baniya, Santosh; Bhatta, Suraj; Subedi, Sachin; Gatterer, Hannes; Rasmussen, Peter; Hilty, Matthias Peter; Sigg, Anne-Aylin; Timalsina, Santosh; Siebenmann, Christoph
errShare
errSave
Complement activation by IgG subclasses is governed by their ability to oligomerize upon antigen binding
errPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
IF9.1
err2024-10-22
err0
errOAAI
errFrischauf, Nikolaus; Borg, Ellen G. F.; Labrijn, Aran F.; Beurskens, Frank J.; Preiner, Johannes
errShare
errSave
Epcoritamab in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma: EPCORE NHL-3 longer-term data
errANNALS OF ONCOLOGY
IF65.4
err2024-10-01
err0
PREAI
errIzutsu, K.; Kumode, T.; Yuda, J.; Nagai, H.; Mishima, Y.; Suehiro, Y.; Yamamoto, K.; Fujisaki, T.; Ishitsuka, K.; Ishizawa, K.; Ikezoe, T.; Nishikori, M.; Akahane, D.; Fujita, J.; Jafarinasabian, P.; Noguchi, H.; Buchbjerg, J.; Favaro, E.; Fukuhara, N.
errShare
errSave
Long-term follow-up shows epcoritamab drives deep, durable responses in relapsed/refractory follicular lymphoma (R/R FL)
errANNALS OF ONCOLOGY
IF65.4
err2024-10-01
err0
PREAI
errIzutsu, K.; Akahane, D.; Toubai, T.; Saito, T.; Mishima, Y.; Fujisaki, T.; Kitawaki, T.; Kumode, T.; Suehiro, Y.; Ishitsuka, K.; Conlon, R.; Noguchi, H.; Buchbjerg, J.; Favaro, E.; Fukuhara, N.
errShare
errSave
Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy
errCLINICAL PHARMACOLOGY & THERAPEUTICS
IF5.5
err2024-09-19
err1
PREAI
errNagaraja Shastri, Prathap; Shah, Nirav; Lechmann, Martin; Mody, Hardik; Retter, Marc W.; Zhu, Min; Li, Tommy; Wang, Jun; Shaik, Naveed; Zheng, Xirong; Ovacik, Meric; Hua, Fei; Jawa, Vibha; Boetsch, Christophe; Cao, Yanguang; Burke, John; Datta, Kaushik; Gadkar, Kapil; Upreti, Vijay; Betts, Alison
errShare
errSave
Agnostic B cell selection approach identifies antibodies against K. pneumoniae that synergistically drive complement activation
errNATURE COMMUNICATIONS
IF15.7
err2024-09-16
err0
errOAAI
errvan der Lans, Sjors P. A.; Bardoel, Bart W.; Ruyken, Maartje; de Haas, Carla J. C.; Baijens, Stan; Muts, Remy M.; Scheepmaker, Lisette M.; Aerts, Piet C.; van't Wout, Marije F. L.; Preiner, Johannes; Marijnissen, Renoud J.; Schuurman, Janine; Beurskens, Frank J.; Kerkman, Priscilla F.; Rooijakkers, Suzan H. M.
errShare
errSave
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma
errJOURNAL OF HEMATOLOGY & ONCOLOGY
IF40.4
err2024-08-16
err0
errOAAI
errRosenthal, Allison; Munoz, Javier; Jun, Monika; Wang, Tongsheng; Mutebi, Alex; Wang, Anthony; Yang, Shibing; Osei-Bonsu, Kojo; Elliott, Brian; Navarro, Fernando Rivas; Yu, Junhua; Brodkin, Samantha; Sacchi, Mariana; Ip, Andrew
errShare
errSave